该BioFire®FilmArray®System通过对传染病诊断进行综合征方法来设置新标准。它在一个快速测试中具有广泛的可能性病原体,最大化在临床相关时间范围内获得正确答案的可能性。
Biofire的客户群包括希望在内部运行全面分子测试的医院,而不是向外部参考实验室发送个人测试。生物传播系统 - 包括系统仪器和消费袋 - 确实为已经支付了测试,设备和治疗的高度美元的医院提供了更高的前期投资和持续成本。
However, the speed, accuracy, and comprehensive target menu of theBioFire®FilmArray®Panelscan facilitate significant long-term cost savings benefits compared to lower-cost standard-of-care options, making it a worthwhile investment that ultimately saves your institution time and money.
Standard-of-Care Testing
1Patient Sample >Multiple Tests Ordered >Results Take Hours to Days >Individual Results in Separate Reports >更长的患者住院住宿
当面对批判性病人时,医院医疗保健提供者通常必须在高准确的测试中仔细选择。测试全面倾向于涉及串行方法,这可能会产生下游成本和浪费宝贵的时间。这意味着当时医生需要提出关键患者管理决策,可能无法识别传染病。
With standard-of-care methods like bacterial culture or targeted influenza tests, the right test might not be ordered first, or it might not be ordered at all. Costs associated with downstream testing may rise, patient care may be prolonged or compromised, and the risks of adverse outcomes and patient dissatisfaction may rise.
生物传输综合征测试
1Patient Sample >1综合测试>About 1 Hour >1个易于阅读的报告中的多个结果>Better Patient Management
生物传染的综合征试验是传染病诊断挑战的前线解决方案。需要一个患者样品和约1小时,生物犯综合征试验靶向与患者特定综合征相关的最常见的病原体和抗微生物抗性基因。随着核酸提取的一体化整合,通过多重PCR扩增,以及检测,这种方法显着提高了鉴定病原体的概率。
A molecular syndromic test can help doctors avoid the laborious guesswork and downstream cost of serial testing. It can promote antimicrobial stewardship and optimize patient management, including admission, isolation, cohorting, and antimicrobial therapy.
该BioFire System is fast, accurate,andcomprehensive, empowering healthcare providers to choose the right test, the first time.
How Does the BioFire System Save Money in the Long Run?
呼吸道Testing
每年,单独的流感占医疗费用高达1670亿美元。1Targeted Flu A/B and RSV testing is the standard of care, but this approach can run the risk of missing several pathogen detections and co-detections. Additionally, these rapid targeted tests tend to have sensitivities ranging from only 50 to 70%.
97.1%的灵敏度,BioFire®FilmArray®呼吸2面板同时测试21个通常的呼吸季节嫌疑人约一小时。2Getting a pathogen-specific result from a front-line test can lead to several cost-saving benefits, including:
- 显着降低了医院的住宿时间3.
- Less time to targeted treatment, including shorter antibiotic durations, avoiding unnecessary antibiotic use, and promoting antimicrobial stewardship goals4.
- More informed infection control decisions, including shortened isolation times and optimal patient cohorting5.
该COVID-19 pandemic has especially brought to light the heavy burdens that respiratory illnesses can place on hospitals and healthcare providers.Click here to learn about BioFire’s syndromic SARS-CoV-2 assay.
肺炎测试
For a single patient with pneumonia, a hospital will spend an average of $36,000 to diagnose and treat them.6.In the US, this economic burden amounts to about $10.6 billion dollars annually.7.
CDC资助的研究表明,护理标准肺炎培养物未鉴定62%-Prover的患者中的病原体。2020年欧洲杯希腊夺冠赔率 detects the nucleic acid of 33 targets, including bacteria, viruses, and antimicrobial resistance genes most associated with pneumonia—even if the organism will not grow in culture.
Rapidly determining the etiology of pneumonia, and helping distinguish colonizing bacteria from true infectious agents with semi-quantitative PCR results, can facilitate these cost-savings benefits:
- De-escalation of antibiotics in up to half of cases for an average reduction of 6.2 days of antibiotic therapy per patient9.
- Adjustment of antibiotic courses in up to 71% of cases10.
- Identification of a pathogen not covered by empiric therapy in patients who failed empiric therapy11.
使用快速的病原体特异性结果使患者能够尽快获得有效的目标治疗患者,可以帮助储备高成本的医院资源,如急诊室访问或ICU床,适用于需要它们的患者。
Bloodstream Infection Testing
血液感染可以成为昂贵的和deadly in just a matter of hours. In fact, septicemia is the most expensive condition treated in US hospitals, accounting for over $23 million in healthcare costs every year.12.Depending on severity, a single case of sepsis costs an average of $7,970 but can cost as much as $44,027.13.
该BioFire®Blood Culture Identification 2 Panelidentifies 43 organisms in positive blood culture 70% faster than standard-of-care methods.14.This can save over $3,000 per patient in overall hospital costs related to sepsis.15.该se savings can provide a variety of benefits to patients and hospitals, including:
- 更少的days spent in the ICU16.,17
- Decreased length of hospital stay16.,17
- Decreased pharmacy costs16.,17
- Reduced treatment for patients with coagulase-negative staphylococci contaminated blood cultures15.
Meningitis/Encephalitis Testing
区分细菌和脑膜炎的细菌和病毒性病因与重要的是挑战性。存在具有类似症状的几种致病病因,以及护理标准测试通常未能鉴定病原体,结果可能需要几天。
A pathogen-specific result from the2020年欧洲杯夺冠热门 - 与中枢神经系统感染相关的最常见的细菌,病毒和真菌的14种测试 - 可以有助于节省多种方式,包括:
- ~2.5x increased pathogen detection compared to standard of care methods, enabling specific etiologic diagnoses18,19
- 对儿科和成人患者的平均2天降低医院的住宿时间20.,21
- Reduced antibiotic and antiviral therapy by 2 days for both pediatric and adult patients20.,22
Gastroenteritis Testing
Traditional stool testing methods are slow, labor intensive, and often fail to reveal the etiology of a patient’s gastrointestinal symptoms. Physicians are frequently left to make patient management decisions without a reliable laboratory result.
该BioFire®FilmArray®Gastrointestinal Paneltargets 22 of the pathogens most likely to cause gastrointestinal infections, including bacteria, viruses, and parasites. Rapid results in one easy-to-read report help physicians identify an organism faster, leading to significant cost savings benefits, including:
- Reducing downstream stool tests and procedures, such as endoscopies, CT scans, X-rays, and ultrasounds23.
- 每位患者减少12小时的平均入住时间24.
- Prescribing fewer antibiotics23.
How Much Does the BioFire System Cost?
船上的精确定价生物传输系统取决于几个因素,这就是您可以在您的机构申请报价或免费示范的原因。
除了正在进行的临床研究中证明的许多潜在下游和长期节省,2020年欧洲杯决赛 与政府和私人付款人以及其他重要利益攸关方合作,以确保综合程序技术(包括普通程序技术)的有利和最新的健康计划政策(CPT®) codes. These报销选择帮助生物传输系统对任何规模机构的可访问投资。
该BioFire Reimbursement and Market Access Team can be reached atreimbursement@biofiredx.comand 385-770-1956. They are available to answer questions about reimbursement rates, coding, denials and appeals, and understanding health plan policies.
References:
- Forum of International Respiratory Societies. (2016) The Global Impact of Respiratory Disease – Second Edition.
- 该stated performance is the aggregate of the prospective data in the BioFire RP2 Panel clinical study.
- Martinez r等人。(2016)CVS海报。
- Brendish N等人。(2017)柳叶刀Resp Med。5(5):401。
- Pettit N, et al. (2015) J. Med Microbiol. 64:312.
- Broulette J,et al.(2013) American Health & Drug Benefits. 6(8):494-503.
- pfunter a,et al.(2013) HCUP Statistical Brief #146.
- 耆那司,et al。(2015) The New England Journal of Medicine. 3(5):415-227.
- Buchan BW,et al。(2020) J Clin Microbiol. Vol. 58.
- 诈骗者,et al.(2019)CVS海报。
- Enne V,et al。(2019)Eccmid海报。
- Torio C,et al。(2016)医疗保健成本和利用率项目。统计简报204。
- CMS.gov. (2015) National and State Summaries of Inpatient Charge Data.https://www.cms.gov/research-statistics-data-andsystems/statistics-trends-and-reports/medicare-provider-charge-data/inpatient2015。
- vacvane s,et al.(2016) J Clin Microbiol. Vol. 54.
- Pardo J,et al.(2016) Diagn Microbiol Infect Dis. 84(2):159-164.
- Cowden R,et al。(2016)IDWeek海报。
- Kim J,et al。(2015)ASM Microbe海报。
- Evans M,et al.(2020)image microbiol感染dis。96(2):114935。
- Posnakoglou L,et al.(2020)EUR J Clin Microbiol感染Dis。
- MOFFA MA,et al.(2020)抗生素(巴塞尔)。26; 9(6):F282。
- O’Brien MP,et al.(2018) Pediatr Infect Dis J. 37(9):868-871.
- Hagen A,et al.(2020)BMC PedIATR。5; 20(1):56。
- Axelrad J,et al。(2019) J Clin Micrbiol. 27;57(3). E01776-18
- Beal S,et al。(2018) J Clin Microbiol. 56(1). E01457-17.